Double-blind randomized comparison of single-dose ciprofloxacin versus intravenous cefazolin in patients undergoing outpatient endourologic surgery.
OBJECTIVE
To compare the efficacy of single-dose oral ciprofloxacin with intravenous cefazolin as a prophylactic agent in patients undergoing outpatient endourologic surgery.


METHODS
One hundred patients were enrolled in a double-blind, randomized study to receive either ciprofloxacin (500 mg) or cefazolin (1 g) before surgery. A postoperative clinical evaluation and urine cultures were performed 5 to 10 days after surgery. Patients undergoing ureteral stent insertion or exchange, ureteroscopy, bladder biopsy, retrograde pyelography, collagen injection, and internal urethrotomy were included.


RESULTS
Postoperative urinary tract infection occurred in 7 (9.1%) of 77 patients, including 3 (8.1%) of 37 and 4 (10.0%) of 40 of those who received ciprofloxacin and cefazolin, respectively (P = 0.77). There were no episodes of sepsis, and no patient with infection required hospitalization. The total cost associated with the administration of prophylactic antibiotics in the study population was $3657 less in those 50 patients who received ciprofloxacin than in the 50 patients who received cefazolin.


CONCLUSIONS
A single oral dose of ciprofloxacin in patients undergoing outpatient endourologic surgery was equally effective as cefazolin in preventing postoperative urinary tract infection, but was associated with markedly lower overall costs.
Christiano
A P
AP
Department of Surgery, University of Chicago Pritzker School of Medicine, Illinois 60637, USA.
Hollowell
C M
CM
Kim
H
H
Kim
J
J
Patel
R
R
Bales
G T
GT
Gerber
G S
GS
D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D002437:Cefazolin / Q000008:administration & dosage* / Q000627:therapeutic use; D002511:Cephalosporins / Q000008:administration & dosage* / Q000627:therapeutic use; D016009:Chi-Square Distribution; D002939:Ciprofloxacin / Q000008:administration & dosage* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D011183:Postoperative Complications / Q000517:prevention & control*; D016896:Treatment Outcome; D014546:Urinary Catheterization; D014552:Urinary Tract Infections / Q000517:prevention & control*; D014570:Urologic Diseases / Q000601:surgery
D000890:Anti-Infective Agents; D002511:Cephalosporins; D002939:Ciprofloxacin; D002437:Cefazolin